EL PASO, TX-- December 5, 2013 - Premier Biomedical, Inc. (OTCQB: BIEI), in concert with The University of Texas at El Paso, has conducted a confirmatory study supporting the ability of its breast cancer therapy to outperform chemotherapy in mice -- those on this regimen had a distinctively higher survival rate, smaller tumor volume, and maintained weight, as opposed to losing body mass as was demonstrated by control subjects on standard chemotherapy.
Most significant was the fact that no mouse treated with Premier Biomedical's treatment regimen developed metastatic disease. Of the mice subjected to more traditional therapies in our confirmatory trial, 20% suffered metastases to the lungs. The tumor burden of metastatic lesions causing systemic wasting of body mass is the number one cause of death in humans struggling with breast cancer. This experimental success may demonstrate the efficacy of Premier Biomedical's breast cancer candidate regimen as an immune-system-modulating therapy precluding metastatic complications.
Full details of the study are being submitted for peer review to the journal of Molecular Cancer Therapeutics in the coming weeks. That report will delve into methodologies and validate the statistical significance of results. It will also highlight a subset of our study in which pre-existing breast cancer was not only completely eradicated in mice after they received Premier's treatment, but subsequent attempts to inject new tumor cells into those mice failed to cause cancer because their immune system was apparently primed to reject it.
"This confirmation of results is a positive indication of Premier Biomedical's ability to bring desperately needed therapy to patients in need. If our breast cancer treatment regimen can successfully prevent metastasis in human patients as it has in mice, then the impact of our therapy on survival rates would be profoundly significant," said William A. Hartman, President and Chief Executive Officer of Premier Biomedical, Inc. "Furthermore, our tests verify that we may not only have developed an effective therapy against pre-existing breast cancer, but may also have discovered an effective means of preventing breast cancer recurrence that needs more targeted development. This may be an industry first against the threat of breast cancer."
Mr. Hartman continued, "The very substantial improvements that our therapy demonstrated over conventional treatments for breast cancer in mice support my intention to apply for a Section 902 'Breakthrough Therapy' fast track designation from the FDA when we have concluded preliminary clinical trials in humans. Much thanks is owed to the partners who have and will continue to provide Premier Biomedical with the support and assistance needed to produce such achievements."
An announcement of the results from Premier Biomedical, Inc.'s now-duplicated breast cancer study has previously been authored and published by The University of Texas at El Paso. That article can be read here: http://newsuc.utep.edu/index.php/research-news/1068-eliminating-disease-research-partnership-shows-promise
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, in collaboration with the University of Texas at El Paso and the US Department of Defense, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in El Paso, Texas, with offices in Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Premier Biomedical, Inc.
SOURCE: Premier Biomedical, Inc.